Harnessing the power of cytokines to restore immune function

OUR FOCUS

Brooklyn ImmunoTherapeutics is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies.

Our most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2a clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.

LATEST NEWS

November 2018

Brooklyn ImmunoTherapeutics Announces Presentation of Positive Results of IRX-2 Therapy in Resectable Breast Cancer and Head and Neck Cancer at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer

[ READ MORE ]

Brooklyn ImmunoTherapeutics Acquires IRX Therapeutics

[ READ MORE ]

Brooklyn ImmunoTherapeutics Announces Results of IRX-2 Therapy in Resectable Breast Cancer and Head and Neck Cancer Accepted for Oral Presentation at the 2018 Annual Meeting of the Society for Immunotherapy of Cancer

[ READ MORE ]